Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Sets Goal For Biosimilar, Drug Promotion Guidances

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration's drug center plans to issue 102 new and revised draft guidances during calendar year 2016, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and abbreviated new drug application (ANDA) refuse-to-receive standards.

You may also be interested in...

Off-Label Debate Between FDA, Industry To Formally Begin After Election

After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.

How To Handle Off-Label Promotion: A Guide From PhRMA And BIO

Industry communication principles offer best practices for combating contrary evidence, refuting third-party comparative effectiveness analyses and sharing real-world evidence addressing health outcomes and costs.

Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes

Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts